DanCann Pharma A/S: Highly promising analysis results

COPENHAGEN, Denmark, 19 January 2022 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the “Company”), a Danish company powered by cannabinoids, hereby announce that the ambitions to enter the European market with inhouse-produced biomaterial during 2022 has been further supported by the in-house analysis results that the Company has obtained after testing the selected cannabis genetics.

DanCann Pharma has now reduced the number of varieties from 95 to nine. The Tetrahydrocannabinol (THC) content of these genetics are in all cases above the general minimum requirements from the market – and such products are in strong demand from many European markets. In addition, a genetic has been identified where the THC content is significantly higher. In the coming period, several final tests will be carried out to finalize the optimal growth conditions for the selected cannabis, to ensure uniform deliveries when the company goes from tests and analysis to actual production of biomaterials.

DanCann Pharma is generally very satisfied with the results of the many tests carried out in Biotech Pharm1 in 2021, which will continue in early 2022 on the way to a final approval of the facilities during mid-2022 for production of cannabis biomaterial - a so-called bulk-product - which DanCann Pharma expects to be able to sell in commercial volumes during end H2-2022.

DanCann Pharma's production facilities are established based on best practices from the pharmaceutical industry in combination with advanced environmentally controlled agricultural technology (CEA) and vertical agriculture. Designed to deliver biomaterials to the European and global market in line with European Union Good Manufacturing Practices (EU-GMP) standards and Good Agricultural and Collection Practices (GACP), and later on to supply the Company’s future biopharmaceutical downstream production.

Jeppe Krog Rasmussen, CEO of DanCann Pharma, comments:

We are continuously collecting relevant data for validation of processes, equipment, and cultivation conditions. We have optimized the process parameters in our advanced production facilities – and now we are in the final phase where we evaluate on the cannabis genetics that the analysis results show us, to select our products and biomaterials for the market. The whole purpose of the many test runs is ultimately to ensure uniformity and consistency in the products, so that we can maximize our output for our production of biomaterials.

Disclaimer

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology.

Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities.

Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this presentation are made as of the date of this presentation and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

About DanCann Pharma

DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma is a vertically integrated, licensed production and distribution Company based in Denmark. The Company focuses on discovering, developing, manufacturing, and commercializing new therapeutic cannabinoids in a wide range of disease areas.

DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen.
For more information, visit: www.dancann.com

For further information, please contact:

Jeppe Krog Rasmussen, CEO
E-mail: jkr@dancann.com
Website: www.dancann.com